我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

基质金属蛋白酶-9对大鼠动脉粥样硬化斑块内血管生成及斑块稳定性的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第3期
页码:
316-317
栏目:
基础研究
出版日期:
2012-06-25

文章信息/Info

Title:
Effects of matrix metalloproteinase-9 on angiogenesis in rat atherosclerosis plaque and plaque stability
作者:
李学远; 田政球; 程文林; 吴 荔; 杜 芬
(黄石市第二医院心内科，湖北 黄石 435002)
Author(s):
LI Xue-yuan;  TINA Zheng-qiu;  CHENG Wen-lin;  WU Li;  DU Fen
(Department of Cardiology, Seand Hospital of Huangshi, Huangshi 435002, Hubei, China)
关键词:
基质金属蛋白酶-9; 血管生成; 斑块稳定性; 强力霉素
Keywords:
matrix metalloproteinase 9;  angiogenesis;  plaque stability;  doxycycline
分类号:
R543.3
DOI:
-
文献标识码:
A
摘要:
目的:研究基质金属蛋白酶-9（MMP-9）与动脉粥样硬化(AS)斑块内血管生成的关系及强力霉素干预的效果。方法： 将36只雄性Wistar大鼠随机分为对照组（A组，普通饮食喂养）、AS组（B组）和强力霉素干预组（C组），B组和C组均给予高脂饮食＋维生素D3腹腔注射，C组同时给予强力霉素腹腔注射。采用酶法并以全自动生化分析仪测量血脂，双抗体夹心ABC-ELISA法检测血清MMP-9的水平。取主动脉切片行HE染色，观察斑块形态，计数易损斑块的数目。对内皮细胞标记物CD34行免疫组织化学染色法以检测斑块内新生血管密度。结果： B组和C组各项血脂的水平无明显差异，但均明显高于A组（P<0.05）。B组和C组血清MMP-9的水平明显高于A组（P<0.05），B组又高于C组（P<0.05）。与B组比较，C组易损斑块数、CD34+面积/扫描面积(R)比均降低(P<0.01)。结论： 强力霉素能增强斑块稳定性，这种作用可能是通过降低MMP-9的水平进而减少了斑块内血管生成。
Abstract:
AIM:To investigate the influence of matrix metalloproteinase-9 on angiogenesis in atherosclerotic plaque stability and the effects of doxycycline. METHODS: Thirty six Wister rats were divided into groups A, B, and C. Rats in group B and C were fed a high-fat diet and received an i.p. injection of vitamin D3, whereas rats in group C were administered an i.p. injection of doxycycline. Serum lipids were measured by enzymatic and automatic biochemical analyzer, and serum MMP-9 levels were measured by double-antibody sandwich ABC-ELISA assay. Plaque morphology was observed by hematoxylin and eosin stain in aortic sections and the number of vulnerable plaques was counted. Neovessel density in the plaque was detected by immunohistochemical staining on the endothelial cell marker CD34. RESULTS: Serum cholesterol levels were similar between group B and C, but higher than levels in group A (P<0.05). Serum MMP-9 levels were markedly different among groups (P<0.05). Compared with group B, the number of vulnerable plaques was markedly reduced in group C. CONCLUSION: Doxycycline can enhance plaque stability. This effect may be accomplished by reducing the levels of MMP-9 and then inhibiting angiogenesis in atherosclerotic plaques.

参考文献/References

[1]Robertson L,Grip L,Mausson Hultén L,et al.Release of protein as well as activity of MMP-9 from unstable athlemsclerotic plaques during percutaneous comnary intervention[J].J Intern Med,2007, 262(6):659-667.

[2]Chen F,Eriksson P,Kimura T,et al.Apoptosis and angiogenesis are induced in the unstable coronary athemselemtic plaque[J].Coronary artery disease,2005,16(3):191-197.

[3]Khurala R,Somons M,Martin JF,et al.Role of angiogenesis in cardiovascular disease:a criticalappraisaI[J].Circulation,2005,112(12):1813-1824.

[4]Celletti FL,Hilfiker PR,Ghafouri P,et al.Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque[J].J Am Coll Cardiol,2001,37(8):2126-2130.

[5]Giansente C,Fiotti N,Di chiara A,et al.In-hospital outcome of patients with acute comnory syndrome:relationship with inflamation and remodeling markers[J].CaIdiovasc Med,2007,8(8):602-607.

[6]Kilic T,Ural D,Uml E,et al.Relation between proinflammatory to anti-Inflamma-tory cytokine ratios and long-tem prognosis in patients with non-ST elevation acute comnary yndmme[J].Healt,2006,92(8):104l-1046.

[7]宋 涛,冯莉萍,夏 豪,等.粥样斑块发生发展过程中炎症和新生内膜血管之间的关系[J].心脏杂志,2006, 18(6):636-639,642.

[8]Kuge Y,Takai N,Ishino S,et al.Distribution profiles of membrane type-1 matrix metalloproteinase(MT1-MMP),matrix metallopmteinase-9 (MMP-9) and cyclooxygenase-2(COX-2) in rabbit atherosclerosis:comparison with plaque instability analysis[J].Biol Pharm Bull,2007, 30(9):1634-1640.

[9]杨大春,马双陶,杨永健,等.急性心肌梗死患者单核细胞PPAR、MCP-1和MMP-9表达及其与冠状动脉病变关系[J].中华实用诊断与治疗杂志,2010,24(11):1048-1052.

[10]Chow AK,Cena J,Schulz R.Acute actions and novel targets of matrix metallo-proteinases in the heart and vasculature[J].Br J Pharmaeol,2007,152(2):189-205.

[11]Batlle M,Perez VF,Garcia PE,et al. Down-regulation of matrix metalloproteinase-9(MMP-9)expression in the myocardium of congestive heart failure patients[J].Transplant Pmc,2007,39(7):2344.

[12]Zeng B,Prasan A,Fung KC,et al.Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease[J].Intern Med J,2005,35(6):331-335.

[13]Pepper MS.Role of the matrix metallop roteinase and plasminogen activator-plasmin systems in angiogenesis[J].Arterioscler Thromb Vasc Biol,2001,21(7):1104-1117.

备注/Memo

备注/Memo:
收稿日期：2011-07-10.通讯作者：田政球，副主任医师，主要从事血管危重症临床防治研究Email:tianzhenqiu1968@163.com 作者简介：李学远，硕士生 Email:lixy1980@126.com
更新日期/Last Update: 2012-05-02